Search - tctmd.com

Displaying 1 - 20 of 334

Sort: Relevancy | Date

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

Presentation ACC 2025

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

Presenter: William Fearon

March 30, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2025

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Presenter: Joo-Yong Hahn

March 29, 2025

Presentation ACC 2025

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

Presenter: Hyo-Soo Kim

March 29, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

News Conference News ACC 2024

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Caitlin E. Cox

April 10, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Advertisement

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Outcomes after FFR-Guided PCI vs. CABG: Final 5-Year Follow-up of the FAME 3 Trial

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Clopidogrel versus Aspirin Monotherapy in Patients with High Ischemic Risk after PCI: SMART-CHOICE 3 Trial

Dual Antiplatelet Therapy After PCI According To Bleeding Risk: HOST-BR RCT

WARRIOR: No Clear Answers on How to Best Treat INOCA

What’s Going to Be Hot at ACC 2025?

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Telemedicine Strategy After MI Scores a Win in TELE-ACS

IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease

Need a Statin for Primary Prevention? There’s an App for That

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content